{"nctId":"NCT01080131","briefTitle":"Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.","startDateStruct":{"date":"2010-03"},"conditions":["Acute Gout"],"count":226,"armGroups":[{"label":"Canakinumab 150 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canakinumab 150 mg","Drug: Placebo to triamcinolone acetonide"]},{"label":"Triamcinolone acetonide 40 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Triamcinolone acetonide 40 mg","Drug: Placebo to canakinumab"]}],"interventions":[{"name":"Canakinumab 150 mg","otherNames":[]},{"name":"Triamcinolone acetonide 40 mg","otherNames":[]},{"name":"Placebo to canakinumab","otherNames":[]},{"name":"Placebo to triamcinolone acetonide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Core Study:\n\nInclusion criteria:\n\n* Meeting the American College of Rheumatology (ACR) 1977 preliminary criteria for the classification of acute arthritis of primary gout\n* Onset of current acute gout flare within 5 days prior to study entry\n* Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS)\n* History of ≥ 3 gout flares within the 12 months prior to study entry\n* Contraindication, or intolerance, or lack of efficacy for non-steroidal anti-inflammatory drugs (NSAID) and/or colchicine\n\nExclusion criteria:\n\n* Rheumatoid arthritis, evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis\n* Presence of severe renal function impairment\n* Use of specified pain relief medications or biologics (corticosteroids, narcotics, paracetamol/acetominophen, ibuprofen, colchicine, IL-blocker, and tumor necrosis factor inhibitor within specified periods prior to study entry\n* Live vaccinations within 3 months prior to randomization\n* Requirement for administration of antibiotics against latent tuberculosis (TB)\n* Refractory heart failure (Stage D)\n* Unstable cardiac arrhythmias or unstable symptomatic coronary ischemia\n* Any active or recurrent bacterial, fungal, or viral infection\n\nExtension Study 1:\n\nInclusion:\n\n\\- Completion of the Core study. A patient was defined as completing the core study if they completed the study up to and including visit 7.\n\nExclusion:\n\n\\- Continuation in this extension study was considered inappropriate by the treating physician.\n\nExtension Study 2:\n\nInclusion Criteria:\n\n* Completion of the first extension study CACZ885H2357E1. A patient was defined as completing the first extension study if they completed the study up to and including Visit 10).\n\nExclusion Criteria:\n\n-Continuation in this second extension study was considered inappropriate by the treating physician.\n\nOther protocol-defined inclusion-exclusion criteria applied to the core and extension studies.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to First New Flare: Survival Analysis During the 12 Weeks of Study","description":"Kaplan-Meier estimates of time to first new flare and confidence intervals were determined. For patients with event, time to event = (date of event - date of first dose of study drug + 1). Patients met definition of new flare if they had: •Flare in joint, not a previously affected joint (at baseline or during study) •Flare in joint previously affected (at baseline or during study) after previous flare in joint has resolved completely. Patients did not meet criterion of having new gout flare if: • Increasing/renewed gout pain in an affected joint before flare has resolved completely.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to at Least a 50% Reduction in Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (VAS)","description":"Kaplan-Meier estimates of the time to at least a 50% reduction in self-assessed pain intensity in the joint most affected at Baseline and the confidence intervals were determined along with 95% confidence interval. Patients scored their pain intensity on a 0-100 mm VAS, ranging from no pain (0) to unbearable pain (100). Scores on the 100 mm linear scale were measured to the nearest millimeter from the left. Pain was scored at Baseline; at 6 and 12 hours post-dose; and at 1, 2, 3, 4, 5, 6, and 7 days post-dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"48.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Complete Resolution of Pain; Survival Analysis","description":"Kaplan-Meier estimates of the time to complete resolution of self-assessed pain intensity in the joint most affected and the confidence interval was determined. Patients scored their pain intensity on a 5-point Likert scale (none, mild, moderate, severe, extreme). Pain was scored at Baseline; 6 and 12 hours; 1, 2, 3, 4, 5, 6, and 7 days post-dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"144.0","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"SF 36 Physical Function Score at Week 12","description":"SF-36 measures impact of disease on overall quality of life (QoL). 36-item survey has 8 subscales that can be aggregated into physical and mental component summary scores. Scores are standardized with the use of norm-based methods based on assessment of the general U.S. population free of chronic conditions. Scores range from 1-100 with a mean=50 and a standard deviation=10. A higher score indicates less impact on QoL. Analysis of covariance (ANCOVA) model was used with treatment group and baseline SF-36 physical function subscore as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.46","spread":"2.786"},{"groupId":"OG001","value":"78.75","spread":"2.820"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least 1 New Gout Flare During the 12 Weeks of the Study","description":"The percentage of participants who experienced at least 1 new gout flare during the 12 week study treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null},{"groupId":"OG001","value":"36.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (VAS) at 72 Hours Post-dose","description":"Patients scored their pain intensity in the joint most affected at Baseline on a 0-100 mm VAS, ranging from no pain (0) to unbearable pain (100), at 72 hours post-dose. Scores on the 100 mm linear scale were measured to the nearest millimeter from the left. The analysis of covariance (ANCOVA) analysis included treatment group, Baseline VAS score, and body mass index (BMI) at Baseline as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":"2.33"},{"groupId":"OG001","value":"31.9","spread":"2.35"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Concentrations","description":"Canakinumab concentration was analyzed in serum by means of a competitive Enzyme-linked immunosorbent assay (ELISA) assay with a lower limit of quantification (LOQ) at 100 ng/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.16","spread":"2.375"}]}]}]},{"type":"SECONDARY","title":"Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (0-100 mm VAS)","description":"Patients scored their pain intensity in the joint most affected at Baseline on a 0-100 mm VAS, ranging from no pain (0) to unbearable pain (100), from 6 hours to 7 days post-dose. Scores on the 100 mm linear scale were measured to the nearest millimeter from the left. The ANCOVA analysis included treatment group, Baseline VAS score, and body mass index (BMI) at Baseline as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.7","spread":"1.94"},{"groupId":"OG001","value":"60.3","spread":"1.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":"2.16"},{"groupId":"OG001","value":"52.0","spread":"2.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.1","spread":"2.39"},{"groupId":"OG001","value":"45.0","spread":"2.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.5","spread":"2.45"},{"groupId":"OG001","value":"38.9","spread":"2.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":"2.33"},{"groupId":"OG001","value":"31.9","spread":"2.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":"2.25"},{"groupId":"OG001","value":"27.7","spread":"2.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":"2.23"},{"groupId":"OG001","value":"25.4","spread":"2.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":"2.20"},{"groupId":"OG001","value":"22.3","spread":"2.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":"2.18"},{"groupId":"OG001","value":"19.5","spread":"2.20"}]}]}]},{"type":"SECONDARY","title":"Self-assessed Pain Intensity in the Joint Most Affected at Last Post-Baseline Measured on a Visual Analog Scale (VAS)","description":"Patient's assessment of gout pain intensity in the most affected joint (on a 0-100 mm VAS) for the last post-baseline flare, ranging from no pain (0) to unbearable pain (100), was summarized up to 7 days after receiving a re-dose of study drug by time point. Scores on the 100 mm linear scale were measured to the nearest millimeter from the left. The covariance analysis included treatment group, Baseline VAS score at that flare, and body mass index (BMI) at Baseline as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.4","spread":"3.07"},{"groupId":"OG001","value":"59.1","spread":"2.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.7","spread":"4.24"},{"groupId":"OG001","value":"53.3","spread":"3.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2","spread":"4.74"},{"groupId":"OG001","value":"43.8","spread":"3.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.3","spread":"4.96"},{"groupId":"OG001","value":"34.2","spread":"3.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.0","spread":"5.12"},{"groupId":"OG001","value":"26.1","spread":"3.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":"4.75"},{"groupId":"OG001","value":"23.4","spread":"3.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","spread":"5.11"},{"groupId":"OG001","value":"21.6","spread":"3.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":"5.04"},{"groupId":"OG001","value":"20.5","spread":"3.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","spread":"5.03"},{"groupId":"OG001","value":"19.1","spread":"3.70"}]}]}]},{"type":"SECONDARY","title":"Time to the First New Gout Flare During 24 Weeks","description":"Kaplan-Meier (KM) estimates of the time to first new flare and confidence intervals were determined. Participants met the definition of a new flare if they had:\n\n* Flare in joint, not a previously affected joint (at baseline or during study)\n* Flare in joint previously affected (at baseline or during study) after previous flare in joint has resolved completely.\n\nParticipants did not meet the criterion of having a new gout flare if they had increasing/renewed gout pain in an affected joint before the flare had resolved completely.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"146","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Number of New Gout Flares Per Patient During 24 Weeks","description":"Patients met definition of new flare if they had:\n\n* Flare in joint, not a previously affected joint(at baseline or during study)\n* Flare in joint previously affected (at baseline or during study) after previous flare in joint has resolved completely.\n\nParticipants did not meet the criterion of having a new gout flare if they had increasing/renewed gout pain in an affected joint before the flare had resolved completely.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"0.694"},{"groupId":"OG001","value":"0.80","spread":"1.115"}]}]}]},{"type":"SECONDARY","title":"Time to First Intake of Rescue Medication","description":"Participants who had difficulty in tolerating their pain were allowed to take rescue medication after the 6-hour post-dose pain assessments as follows:\n\n* Acetaminophen (paracetamol) 500 mg and/ or codeine 30 mg as required. A maximum of 1 g/dose or 3 g/day of acetaminophen and 30 mg/ dose or 180 mg/day of codeine was allowed.\n* If they had insufficient pain relief, participants were allowed to take a maximum of 30 mg of oral prednisolone as required per day for 2 days followed by up to 20 mg of prednisolone as required subsequent days within 7 days of a gout flare.\n\nUse of these treatments during the first 7 days of a gout flare was recorded as rescue medication.\n\nKaplan-Meier estimates of the time to first intake of rescue medication, in hours, and the confidence interval were determined for the flare experienced at study entry (Baseline flare) and the last new flare (last post-baseline flare) that occurred up until the end of the first extension period (24 weeks).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"37.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Took Rescue Medication","description":"Participants who had difficulty in tolerating their pain were allowed to take rescue medication after the 6-hour post-dose pain assessments as follows:\n\n* Acetaminophen (paracetamol) 500 mg and/ or codeine 30 mg as required. A maximum of 1 g/dose or 3 g/day of acetaminophen and 30 mg/ dose or 180 mg/day of codeine was allowed.\n* If they had insufficient pain relief, participants were allowed to take a maximum of 30 mg of oral prednisolone as required per day for 2 days followed by up to 20 mg of prednisolone as required subsequent days within 7 days of a gout flare.\n\nUse of these treatments during the first 7 days of a gout flare was recorded as rescue medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":null},{"groupId":"OG001","value":"57.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null},{"groupId":"OG001","value":"41.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Amount of Rescue Medication Taken","description":"Patients who had difficulty in tolerating their pain were allowed to take rescue medication after the 6-hour post-dose pain assessments as follows:\n\n* Acetaminophen (paracetamol) 500 mg and/ or codeine 30 mg as required. A maximum of 1 g/dose or 3 g/day of acetaminophen and 30 mg/ dose or 180 mg/day of codeine was allowed.\n* If they had insufficient pain relief, patients were allowed to take a maximum of 30 mg of oral prednisolone as required per day for 2 days followed by up to 20 mg of prednisolone as required subsequent days within 7 days of a gout flare.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1375.0","spread":"2726.63"},{"groupId":"OG001","value":"2526.5","spread":"3925.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2","spread":"100.40"},{"groupId":"OG001","value":"60.6","spread":"144.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":"35.32"},{"groupId":"OG001","value":"19.3","spread":"44.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2292.0","spread":"3462.65"},{"groupId":"OG001","value":"1541.3","spread":"3771.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.8","spread":"224.11"},{"groupId":"OG001","value":"65.2","spread":"178.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"14.46"},{"groupId":"OG001","value":"18.3","spread":"48.00"}]}]}]},{"type":"SECONDARY","title":"Physician's Global Assessment of Response to Treatment","description":"The study physician made a global assessment of the patient's response to treatment using a 5-point Likert scale: Very good, good, fair, poor, very poor. The percentage of patients in each category is reported. The physician completed the assessment without viewing any of the patient's own assessments (pain intensity and patient's global assessment of response to treatment).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.0","spread":null},{"groupId":"OG001","value":"25.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.0","spread":null},{"groupId":"OG001","value":"35.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null},{"groupId":"OG001","value":"26.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"6.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"5.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.2","spread":null},{"groupId":"OG001","value":"66.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null},{"groupId":"OG001","value":"29.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Events, Death and Serious Adverse Events During 24 Weeks","description":"This was primary endpoint of extension study 1. Adverse event is defined as any unfavorable and unintended diagnosis, symptom sign including an abnormal laboratory finding, syndrome or disease which either occurs during the study, having been absent at baseline, or, if present at baseline, appears to worsen. A serious adverse event is defined as any untoward medical occurrence that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient's Global Assessment of Response to Treatment","description":"Participants made a global assessment of response to treatment using a 5-point Likert scale: Excellent, good, acceptable, slight, poor. The percentage of participants in each category is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","spread":null},{"groupId":"OG001","value":"19.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.0","spread":null},{"groupId":"OG001","value":"32.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"13.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"9.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.5","spread":null},{"groupId":"OG001","value":"40.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.6","spread":null},{"groupId":"OG001","value":"44.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"13.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician's Assessment of Tenderness, Swelling, and Erythema of the Most Affected Joint","description":"The study physician assessed the most affected joint for: Tenderness on a 0-3 point scale: No pain, patient states that \"there is pain\", patient states \"there is pain and winces\", and patient states \"there is pain, winces, and withdraws\" on palpation or passive movement of the affected study joint; Swelling on a 0-3 point scale: No swelling, palpable, visible, and bulging beyond the joint margins; and Erythema: Present or absent. The percentage of participants in each category is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null},{"groupId":"OG001","value":"30.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null},{"groupId":"OG001","value":"46.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"14.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":null},{"groupId":"OG001","value":"91.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":null},{"groupId":"OG001","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null},{"groupId":"OG001","value":"35.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null},{"groupId":"OG001","value":"29.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":null},{"groupId":"OG001","value":"28.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"6.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.7","spread":null},{"groupId":"OG001","value":"94.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.2","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null},{"groupId":"OG001","value":"97.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician's Assessment of Range of Motion of the Most Affected Joint","description":"The study physician assessed the range of motion of the most affected joint for range of motion on a 5-point Likert scale: Normal, mildly restricted, moderately restricted, severely restricted, immobilized. The percentage of participants in each category is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null},{"groupId":"OG001","value":"28.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.4","spread":null},{"groupId":"OG001","value":"45.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":null},{"groupId":"OG001","value":"20.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"5.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.1","spread":null},{"groupId":"OG001","value":"97.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Events, Death and Serious Adverse Events (72 Weeks Overall)","description":"This was the primary endpoint of extension study 2. An adverse event was defined as any unfavorable and unintended diagnosis, symptom sign including an abnormal laboratory finding, syndrome or disease which either occurs during the study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse event is defined as any untoward medical occurrence that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"39","spread":null},{"groupId":"OG003","value":"70","spread":null},{"groupId":"OG004","value":"29","spread":null},{"groupId":"OG005","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"High-sensitivity C-reactive Protein (hsCRP) and Serum Amyloid A Protein (SAA) Levels","description":"High sensitivity C-reactive protein (hsCRP) and serum amyloid A (SAA) were determined in blood serum in order to identify the presence of inflammation, to determine its severity, and to monitor the response to treatment. Analyses were measured by a central laboratory. The analysis included treatment group, log-transformed protein level at baseline, and body mass index (BMI) at baseline as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.84","spread":null},{"groupId":"OG001","value":"6.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.31","spread":null},{"groupId":"OG001","value":"15.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.69","spread":null},{"groupId":"OG001","value":"4.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.74","spread":null},{"groupId":"OG001","value":"11.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient's Assessment of Gout Pain Intensity in the Most Affected Joint","description":"Participant scored their current pain intensity in the most affected joint of the gout flare on a 5-point Likert Scale (none, mild, moderate, severe, extreme).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":null},{"groupId":"OG001","value":"18.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null},{"groupId":"OG001","value":"45.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","spread":null},{"groupId":"OG001","value":"27.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"8.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.2","spread":null},{"groupId":"OG001","value":"67.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":null},{"groupId":"OG001","value":"25.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"7.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Maximum Severity of New Gout Flares as Severe or Extreme","description":"For each new flare, participants scored the maximum amount of acute gout pain in the most affected joint since the onset of the new flare and the time they were re-dosed on a 5 point Likert scale as None, Mild, Moderate, Severe or Extreme. The percentage of participants with a maximum new flare severity of severe or extreme is reported for the first post-baseline flare that occurred during the 12-week core study and for the last post-baseline flare that occurred up until the end of the first extension period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"78.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.0","spread":null},{"groupId":"OG001","value":"78.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First New Flare: Survival Analysis by Treatment Over 72 Weeks","description":"Kaplan-Meier estimates of time to first new flare and confidence intervals were determined. For patients with event, time to event = (date of event - date of first dose of study drug + 1).\n\nPatients met definition of new flare if they had:\n\n* Flare in joint, not a previously affected joint (at baseline or during study)\n* Flare in joint previously affected (at baseline or during study) after previous flare in joint has resolved completely.\n\nPatients did not meet criterion of having new gout flare if:\n\n• Increasing/renewed gout pain in an affected joint before flare has resolved completely.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"254.0","spread":null},{"groupId":"OG001","value":"146.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Flare Rate Per Year","description":"Flare rate was calculated as the number of new flares over the period of observation in years. Flare rate was calculated using only those new flares before switching to canakinumab.\n\nParticipants met the definition of new flare if they had:\n\n* Flare in joint, not a previously affected joint (at baseline or during study)\n* Flare in joint previously affected (at baseline or during study) after previous flare in joint has resolved completely.\n\nParticipants did not meet criterion of having new gout flare if:\n\n• Increasing/renewed gout pain in an affected joint before the flare has resolved completely.\n\nFlare rates were estimated from a negative binomial model with body mass index at baseline as a covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.18","spread":null},{"groupId":"OG001","value":"2.02","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient's Assessment of Gout Pain Intensity for Participants Re-treated or Switched to Canakinumab","description":"Participants scored their current pain intensity in the most affected joint of the gout flare on a 5-point Likert Scale (none, mild, moderate, severe or extreme).\n\nData are reported for the last post-baseline flare for participants who were randomized to and re-treated with canakinumab, and for the first post-baseline flare treated with canakinumab for participants randomized to triamcinolone acetonide and who were switched to canakinumab in extension study 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.5","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.1","spread":null},{"groupId":"OG001","value":"62.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":null},{"groupId":"OG001","value":"12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.9","spread":null},{"groupId":"OG001","value":"59.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.1","spread":null},{"groupId":"OG001","value":"35.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null},{"groupId":"OG001","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient's Global Assessment of Response to Treatment for Participants Re-treated or Switched to Canakinumab","description":"Participants made a global assessment of response to treatment using a 5-point Likert scale: Excellent, good, acceptable, slight or poor. Data are reported for the last post-baseline flare for participants who were randomized to and re-treated with canakinumab, and for the first post-baseline flare treated with canakinumab for participants randomized to triamcinolone acetonide and who were switched to canakinumab in extension study 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.4","spread":null},{"groupId":"OG001","value":"36.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","spread":null},{"groupId":"OG001","value":"39.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"21.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.8","spread":null},{"groupId":"OG001","value":"51.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician's Global Assessment of Response to Treatment for Participants Re-treated or Switched to Canakinumab","description":"The study physician made a global assessment of the patient's response to treatment using a 5-point Likert scale: very good, good, fair, poor or very poor.\n\nThe physician completed the physician's global assessment of response to treatment without viewing any of the patient's assessments.\n\nData are reported for the last post-baseline flare for participants who were randomized to and re-treated with canakinumab, and for the first post-baseline flare treated with canakinumab for participants randomized to triamcinolone acetonide and who were switched to canakinumab in extension study 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":null},{"groupId":"OG001","value":"42.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":null},{"groupId":"OG001","value":"39.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null},{"groupId":"OG001","value":"18.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.9","spread":null},{"groupId":"OG001","value":"59.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.9","spread":null},{"groupId":"OG001","value":"38.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician's Assessment of Joint Tenderness for Participants Re-treated or Switched to Canakinumab","description":"The study physician assessed the most affected joint for tenderness on the following 4-point scale:\n\n* no pain;\n* participant states that \"there is pain;\n* participant states \"there is pain and winces\";\n* participant states \"there is pain, winces and withdraws\" on palpation or passive movement of the affected study joint.\n\nData are reported for the last post-baseline flare for participants who were randomized to and re-treated with canakinumab, and for the first post-baseline flare treated with canakinumab for participants randomized to triamcinolone acetonide and who were switched to canakinumab in extension study 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.8","spread":null},{"groupId":"OG001","value":"42.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.1","spread":null},{"groupId":"OG001","value":"79.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":null},{"groupId":"OG001","value":"20.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician's Assessment of Joint Swelling for Participants Re-treated or Switched to Canakinumab","description":"The study physician assessed the most affected joint for swelling on the following 4-point scale:\n\n* no swelling;\n* palpable;\n* visible;\n* bulging beyond the joint margins.\n\nData are reported for the last post-baseline flare for participants who were randomized to and re-treated with canakinumab, and for the first post-baseline flare treated with canakinumab for participants randomized to triamcinolone acetonide and who were switched to canakinumab in extension study 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","spread":null},{"groupId":"OG001","value":"47.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null},{"groupId":"OG001","value":"34.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"15.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.7","spread":null},{"groupId":"OG001","value":"79.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","spread":null},{"groupId":"OG001","value":"17.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician's Assessment of Erythema for Participants Re-treated or Switched to Canakinumab","description":"The study physician assessed the most affected joint for erythema (redness of the skin) as either present, absent or not assessable.\n\nData are reported for the last post-baseline flare for participants who were randomized to and re-treated with canakinumab, and for the first post-baseline flare treated with canakinumab for participants randomized to triamcinolone acetonide and who were switched to canakinumab in extension study 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2","spread":null},{"groupId":"OG001","value":"92.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null},{"groupId":"OG001","value":"7.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.5","spread":null},{"groupId":"OG001","value":"94.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"5.1","spread":null}]}]}]},{"type":"SECONDARY","title":"High-sensitivity C-reactive Protein (hsCRP) Levels for Participants Re-treated With or Switched to Canakinumab","description":"High sensitivity C-reactive protein (hsCRP) levels in blood serum were measured by a central laboratory in order to identify the presence of inflammation, to determine its severity, and to monitor the response to treatment.\n\nData are reported for the last post-baseline flare for participants who were randomized to and re-treated with canakinumab, and for the first post-baseline flare treated with canakinumab for participants randomized to triamcinolone acetonide and who were switched to canakinumab in extension study 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":"64.11"},{"groupId":"OG001","value":"39.4","spread":"41.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"31.11"},{"groupId":"OG001","value":"12.6","spread":"15.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"4.97"},{"groupId":"OG001","value":"3.5","spread":"5.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"2.30"},{"groupId":"OG001","value":"2.2","spread":"3.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"4.41"},{"groupId":"OG001","value":"2.4","spread":"4.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"0.79"},{"groupId":"OG001","value":"2.9","spread":"4.90"}]}]}]},{"type":"SECONDARY","title":"Serum Amyloid A Protein (SAA) Levels for Participants Re-treated With or Switched to Canakinumab","description":"Serum Amyloid A Protein (SAA) levels in blood serum were measured by a central laboratory in order to identify the presence of inflammation, to determine its severity, and to monitor the response to treatment.\n\nData are reported for the last post-baseline flare for participants who were randomized to and re-treated with canakinumab, and for the first post-baseline flare treated with canakinumab for participants randomized to triamcinolone acetonide and who were switched to canakinumab in extension study 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129.0","spread":"324.45"},{"groupId":"OG001","value":"145.9","spread":"257.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6","spread":"163.45"},{"groupId":"OG001","value":"45.4","spread":"97.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"8.90"},{"groupId":"OG001","value":"5.9","spread":"8.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"3.67"},{"groupId":"OG001","value":"5.0","spread":"7.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"4.24"},{"groupId":"OG001","value":"5.3","spread":"13.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"2.37"},{"groupId":"OG001","value":"4.8","spread":"5.94"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":112},"commonTop":["Hypertension","Arthralgia","Upper respiratory tract infection","Back pain","Headache"]}}}